Catalyst
Slingshot members are tracking this event:
Seattle Genetics expected to report data in 2016 from a phase 1b trial of 33A in combination with cytarabine and daunorubicin for frontline, younger AML patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 03, 2016
Occurred Source:
http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2227324
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cytarabine, Daunorubicin, Young Aml Patients, Phase 1b Data, Vadastuximab Talirin
